Ruxolitinib: all 324 studies that test it
Page 1 of 4. Open to participants first (83), then studies with results posted, then the rest; newest registration first within each.
- A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative NeoplasmsRecruitingNCT07849231Phase 1
- Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingNCT07840456Phase 2
- Topical Ruxolitinib in Acute Skin GVHD (Graft Versus Host Disease)Not yet recruitingNCT07801248Phase 1
- Sirolimus+Ruxolitinib+Mycophenolate Mofetil for Prophylaxis of aGVHD in Patients Receiving Haplo-HSCT Who Are Intolerant to CNINot yet recruitingNCT07796620Phase 1/2
- Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumRecruitingNCT07783412Phase 2
- Opzelura Experience StudyNot yet recruitingNCT07661979Phase 4
- Belumosudil With Ruxolitnib as Third Line Therapy for Chronic Graft Versus Host Disease (cGvHD)Not yet recruitingNCT07643025Phase 2
- Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental VitiligoNot yet recruitingNCT07595939Phase 3
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingNCT07588945Phase 3
- A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid TumorsNot yet recruitingNCT07566897Phase 1
- Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell TransplantationRecruitingNCT07548983Phase 1
- Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in MyelofibrosisRecruitingNCT07521046Phase 1
- Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)RecruitingNCT07509749Phase 2
- Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell CountsNot yet recruitingNCT07498205Phase 4
- CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid LeukemiaRecruitingNCT07464951Phase 1
- Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)RecruitingNCT07424222Phase 1
- Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic MalignanciesRecruitingNCT07366801Phase 2/3
- A Study of Ruxolitinib for Preventing Graft-Versus-Host Disease in People With a Hematologic Malignancy Who Will Receive a Stem Cell TransplantRecruitingNCT07359859Phase 2
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell LymphomaRecruitingNCT07356245Phase 2
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingNCT07352566Phase 4
- Novel First-line Therapies for Grade II Acute GVHD(Graft-versus-host Disease )RecruitingNCT07340723Phase 2
- Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic LeukemiaRecruitingNCT07311746Phase 1/2
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingNCT07297914Phase 2/3
- Amping up With PemJAKRecruitingNCT07283822Phase 2
- Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell LymphomasRecruitingNCT07278856Phase 1
- Ruxolitinib-Enhanced Haplo HCT for Children and Young Adults With Sickle Cell DiseaseRecruitingNCT07252050Phase 1/2
- Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell TransplantationRecruitingNCT07249346Phase 2
- Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched DonorRecruitingNCT07238712Phase 2
- Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap SyndromesRecruitingNCT07228624Phase 2
- Retifanlimab and Ruxolitinib In Solid MalignanciesRecruitingNCT07219576Phase 1/2
- MRD-positive AML Clinical StudyRecruitingNCT07131059Not applicable
- Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML)RecruitingNCT07128381Phase 1/2
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized TrialRecruitingNCT07101588Phase 4
- Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman DiseaseRecruitingNCT07085039Phase 2
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis SuppurativaRecruitingNCT07049575Phase 1
- Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell TransplantationRecruitingNCT07025538Phase 1
- Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed GlioblastomaRecruitingNCT06991101Phase 2
- A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophosphamide, Sirolimus, Mycophenolate Mofetil to Prevent Graft Versus Host DiseaseRecruitingNCT06973668Phase 2
- Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host DiseaseRecruitingNCT06824103Phase 4
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Children (6 to < 12 Years Old) With Nonsegmental VitiligoRecruitingNCT06804811Phase 3
- A Study of Ruxolitinib in Combination With Ulixertinib in People With MyelofibrosisRecruitingNCT06773195Phase 1/2
- Comparing the Therapeutic Effects of Using Ruxolitinib and Steroids Concurrently to Steroids Alone as Initial Treatment In Patients Diagnosed With Chronic Graft-versus-host Disease at a Grade of Moderate or Higher SeverityRecruitingNCT06756061Phase 2
- Topical Ruxolitinib for Face and Neck Vitiligo of Adult Chinese Patients Refractory to Topical TacrolimusRecruitingNCT06719024Phase 2/3
- Ruxolitinib vs Prednisone as First-line Therapy for cGVHD Needing Systemic TherapyRecruitingNCT06660355Phase 2
- Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate CancerRecruitingNCT06616155Phase 1/2
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingNCT06615050Phase 3
- REscuing Bone Marrow Function in Patients with AplaStic AnaEmia and Bone Marrow FaiLure Post AllogEneiC Transplantation 2Not yet recruitingNCT06607367Phase 1/2
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental VitiligoRecruitingNCT06548360Phase 3
- Ruxolitinib Treatment in Inclusion Body MyositisRecruitingNCT06536166Phase 2
- Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell LymphomaRecruitingNCT06508463Phase 1
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With SplenomegalyRecruitingNCT06345495Phase 2
- Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene MutationRecruitingNCT06291987Phase 1
- JAK Inhibitor in Acquired Hemophagocytic synDrome in the Intensive Care UnitNot yet recruitingNCT06244862Phase 2
- Ruxolitinib Plus Fostamatinib for Steroid Refractory cGvHDRecruitingNCT06233110Phase 1
- A Trial of Selinexor, Ruxolitinib and MethylprednisoloneRecruitingNCT06225310Phase 1
- PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of ImmunityRecruitingNCT06199427Phase 2
- Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH)RecruitingNCT06160791Phase 2
- Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic SyndromeRecruitingNCT06128070Phase 2
- MAP-guided Preemptive Therapy of aGvHD by RuxolitinibNot yet recruitingNCT06075225Phase 2
- A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative NeoplasmsRecruitingNCT06034002Phase 1
- Neratinib in Combination With Ruxolitinib in Patients With mTNBCRecruitingNCT06008275Early Phase 1
- Ruxolitinib as GVHD Prophylaxis in AA PatientsNot yet recruitingNCT05914714Phase 2
- Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PVRecruitingNCT05870475Phase 2
- Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPNRecruitingNCT05817955Phase 2
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH)RecruitingNCT05762640Phase 2
- HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological MalignanciesRecruitingNCT05745714Phase 1/2
- A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of MyelofibrosisRecruitingNCT05714072Phase 1
- Prevention of Severe Acute Graft-versus-host Disease in Pediatric Patients Using a daGOAT ModelRecruitingNCT05599256Phase 2
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic LeukemiaRecruitingNCT05592015Phase 2
- Cytokine Guided Risk Stratification and Treatment in Pediatric Hemophagocytic LymphohistiocytosisRecruitingNCT05491304Phase 4
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingNCT05398809Phase 2
- Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibRecruitingNCT05280509Phase 1/2
- Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung CancerRecruitingNCT05098210Phase 1
- A Study of Elritercept Alone or Together With Ruxolitinib in Adults With MyelofibrosisRecruitingNCT05037760Phase 2
- A Study of Ruxolitinib and Duvelisib in People With LymphomaRecruitingNCT05010005Phase 1
- Ruxolitinib in Thrombocythemia and Polycythemia VeraRecruitingNCT04644211Phase 2
- Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic AdenocarcinomaRecruitingNCT04303403Phase 1
- Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative NeoplasmsRecruitingNCT04282187Phase 2
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingNCT04116502Phase 3
- Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)RecruitingNCT04061421Phase 1/2
- Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin LymphomaRecruitingNCT03681561Phase 1/2
- Ruxolitinib and Chemotherapy in Adolescents and Young Adults With Ph-like Acute Lymphoblastic LeukemiaRecruitingNCT03571321Phase 1
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingNCT02974647Phase 2
- A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic DermatitisCompletedNCT06238817Phase 3Results posted
- JAK1/2 Inhibitor Ruxolitinib for Relapsed/Refractory Immune Bone Marrow FailureActive, not recruitingNCT05998408Phase 1/2Results posted
- JAK/STAT Inhibition in CNS Kohlmeier-Degos DiseaseCompletedNCT05998395Phase 1/2Results posted
- Topical Ruxolitinib Evaluation in Chronic Hand EczemaCompletedNCT05906628Phase 2Results posted
- Ruxolitinib in Seborrheic DermatitisCompletedNCT05787860Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05764161Phase 3Results posted
- A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)CompletedNCT05755438Phase 3Results posted
- A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital VitiligoCompletedNCT05750823Phase 2Results posted
- The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance.TerminatedNCT05696392Phase 4Results posted
- Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis SuppurativaCompletedNCT05635838Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Lichen SclerosusCompletedNCT05593445Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Cutaneous Lichen PlanusCompletedNCT05593432Phase 2Results posted
- Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies.TerminatedNCT05579769Phase 2Results posted
- Study of Ruxolitinib Cream in Adolescents With Atopic DermatitisCompletedNCT05456529Phase 3Results posted
- Topical Ruxolitinib in Chronic Hand DermatitisCompletedNCT05293717Phase 1/2Results posted
- Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis InvolvementCompletedNCT05127421Phase 2Results posted
- A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)CompletedNCT04921969Phase 3Results posted